plenty of negative sentiment around at the moment. I keep...

plenty of negative sentiment around at the moment. I keep looking forward to what will happen in the short and longer term.

TGA APPROVAL

could drop on Monday or another couple of weeks. either way very close. what will it open up?

-Anteo will be able to start promoting how good our test is. what results the new trials have achieved, I suspect higher than 97.3% we got from VIDRL with  VTM interference
-Be able to sell in Australia and NZ. Abacus with it's pipeline of customers will be able to start selling
-lead to Indian regulatory approval
-allow the pathway for FDA approval to begin and US market entry. have had ellume's marketing team working with us since September

COUNTRY REGULATIONS.

have Italy and Spain granted, Greece and Turkey very close, clinical trial started in Malaysia and Phillipines, UK in stage 3 of DHSC approval. (Germany and France?)

Anteotech have been pretty forthright with suggestion of deals with Italian pharmacies and Spanish hospitals. we have been told that a lot of our distributors have being trialling with their customer base.

they are some near term, other near term or a bit longer

-Ellume deal
-sepsis test trials
-covid/flu multiplex test trial
-cassette assembly partners
-new 3rd party manufacturers
-setting up our manufacturing base
-new reader platform
-increase distribution network

probably left some out. a lot is happening. has it been slower than hoped for. yes. but are actual sales very close to happening. IMO yes.

again we had many anteotech staff like Operon, with their presentation "There she is our colleague Mrs. Virginia León, lateral flow product specialist, presenting the webinar “The true cost of a 1 USD per test: to automate or not to automate the production” at the Advanced Lateral Flow Conference"
https://www.linkedin.com/feed/update/urn:li:activity:6863468931068248064/

we don't need to sell many tests at a manufacturing cost of $1USD per test to start building substantial revenue.

we have 32m + manufacturing next year and will have covid and sepsis tests available, back of an envelop calculations on $2-$5 profit margins?

IMO, the wait is nearly over, revenue is coming !!! and we have our battery division as well. management have said many times that commercialisation will be around the end of CY 2021. thats not far away... GLTAH